Becker's Healthcare November 29, 2022
Penn Medicine researchers are targeting a “cornucopia of antigens” with mRNA-based technology to develop a universal flu vaccine, and human clinical trials for the 20-subtype candidate are in the works.
The multivalent vaccine employs mRNA technology, which sped up the development and use of the first COVID-19 vaccines. The flu vaccine candidate produces copies of all 20 known influenza subtypes, and animal testing shows reductions in signs of illness and more protections from death, according to a Nov. 25 news release from the Philadelphia-based university and a study published in Science.
“For a conventional vaccine, immunizing against all these subtypes would...
Today's Sponsors
Today's Sponsor